论文部分内容阅读
在美国,头颈部鳞癌(SCCHN)约占全部恶性肿瘤的5%,早期(Ⅰ、Ⅱ期)患者对手术治疗和(或)放疗是有效的。但大多数晚期患者对局部治疗无效。大量的研究已经明确SCCHN的发生与免疫缺陷有关,包括细胞免疫缺陷和体液免疫缺陷,并与SCCHN患者的不良预后有关。因此,免疫调节治疗(如干扰素)对复发的SCCHN患者是一种切实可行的方法。干扰素(IFN)是一类在诱导剂作用下由真核细胞产生的激素样诱导蛋白,它具有抗病毒、抗增殖和免疫学作用,
In the United States, squamous cell carcinoma of the head and neck (SCCHN) accounts for about 5% of all malignancies. Early stage (I, II) patients are effective for surgical treatment and/or radiotherapy. However, most of the advanced patients have no effect on local treatment. A large number of studies have identified that the occurrence of SCCHN is associated with immunodeficiency, including cellular and humoral immune defects, and is associated with a poor prognosis in patients with SCCHN. Therefore, immunomodulatory therapy (such as interferon) is a practical method for patients with relapsed SCCHN. Interferons (IFNs) are hormone-like inducible proteins produced by eukaryotic cells under the action of an inducing agent and have antiviral, antiproliferative, and immunological effects.